Watchlist Price Alert

Relay Therapeutics Inc. (RLAY)

NASDAQ: RLAY · Real-Time Price · USD

2.96

0.11 (3.86%)

At close: May 28, 2025, 3:59 PM

3.00

1.18%

After-hours: May 28, 2025, 04:39 PM EDT

3.86% (1D)

Bid	2.8
Market Cap	508.33M
Revenue (ttm)	7.68M
Net Income (ttm)	-333.39M
EPS (ttm)	-2.2
PE Ratio (ttm)	-1.35
Forward PE	-1.58
Analyst	Buy

Ask	3
Volume	1,270,746
Avg. Volume (20D)	2,599,845
Open	2.85
Previous Close	2.85
Day's Range	2.85 - 3.06
52-Week Range	1.77 - 10.72
Beta	1.66

About RLAY

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol RLAY

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for RLAY stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

3 weeks ago

-5.12%

Relay Therapeutics shares are trading lower follow... Unlock content with Pro Subscription

5 months ago

+12.42%

Relay Therapeutics shares are trading higher after the company announced updated interim clinical data for RLY-2608.

News

6 days ago · zacks.com

What Makes Relay Therapeutics (RLAY) a New Buy Stock

Relay Therapeutics (RLAY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 month ago · zacks.com

Top Cancer Stocks to Buy to Boost Your Portfolio's Health

If the cancer space appeals to you, it's time to consider stocks like Pyxis Oncology, Verastem Oncology and Relay Therapeutics.

1 month ago · seekingalpha.com

Relay Therapeutics: Trying To Find That Right Price

Relay Therapeutics' pipeline has shifted, with the FGFR2 inhibitor lirafugratinib outlicensed to Elevar, bringing in cash and royalties, but losing global rights. RLY-2608, a PI3K-alpha inhibitor, sho...

2 months ago · zacks.com

Down -31.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Relay Therapeutics (RLAY)

The heavy selling pressure might have exhausted for Relay Therapeutics (RLAY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street ...